Drug
Tafluprost clinical trials
- studies test it
- 15
- open now
- 0
- in phase 3
- 4
- first study started
- 2005
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 4
- Phase 4
- 9
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 8
Santen Oy (3) · Santen Pharmaceutical (Taiwan) Co., LTD (1) · Aristotle University Of Thessaloniki (1) · Santen Inc. (1) · Ordination Dr. Hommer (1) · Gangnam Severance Hospital (1) · Dr. Anton Hommer (1) · FinnMedi Oy (1)
Often tested with
Tested in the same studies.
Latanoprost (2) · Timolol (2) · Dorzolamide (1) · Omidenepag isopropyl (1) · Travoprost (1)
Studies
Open first, then newest update. How each study uses tafluprost is read from its arms, and is right about nine times in ten.
Testing it · 15
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.Status unknownPhase 4Fondazione G.B. Bietti, IRCCSNCT05299593Written as tafluprost/timolol
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNot applicableSanten Pharmaceutical (Taiwan) Co., LTDNCT04737928Written as tafluprost
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined TherapyCompletedPhase 4Aristotle University Of ThessalonikiNCT02802137Written as tafluprost
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedPhase 1/2Santen Inc.NCT01654484Written as 0.0015% tafluprost
- A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film ThicknessCompletedPhase 4Ordination Dr. HommerNCT03204487Written as Tafluprost 15µg/ml
- Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma PatientsCompletedPhase 4Gangnam Severance HospitalNCT03104621Written as 0.0015% tafluprost
- Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/mlStatus unknownPhase 4Universitaire Ziekenhuizen KU LeuvenNCT02471105Written as Tafluprost Unit Dose Preservative Free 15microgram/ml
- An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and MoreCompletedPhase 4Dr. Anton HommerNCT01979913Written as Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
- The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With GlaucomaCompletedPhase 4FinnMedi OyNCT01369771Written as Tafluprost 0.0015%
- Switching From Preserved to Preserved-free Treatments for Glaucoma.Status unknownPhase 3Paolo FogagnoloNCT01433900Written as Tafluprost
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsCompletedPhase 3Santen OyNCT01087671Written as tafluprost
- Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)CompletedPhase 4Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaNCT01162603Written as TAFLUPROST 0.0015% EYEDROPS
- Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedPhase 4Alcon ResearchNCT00966940Written as Tafluprost 0.0015% ophthalmic solution
- Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationCompletedPhase 3Santen OyNCT00918346Written as Tafluprost 0.0015%
- Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye DropsCompletedPhase 3Santen OyNCT00596791Written as tafluprost
As the comparator · 2 — what is tested is compared with tafluprost
- DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%CompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01342081Written as Tafluprost ophthalmic solution 0.0015%
- Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsCompletedPhase 3Santen OyNCT01306461Written as Timolol and Tafluprost
Codes
What other systems call tafluprost · ClinicalTrials.gg INT004643
- MeSH (NLM) C485333tafluprostOne source NLM
- UNII (FDA) 1O6WQ6T7G3TAFLUPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 1244607Confirmed FDA, Wikidata
- Wikidata Q2139543tafluprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87385TafluprostOne source FDA
- DrugBank DB08819One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C485333 | tafluprost | One source NLM |
| UNII (FDA) | 1O6WQ6T7G3 | TAFLUPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1244607 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2139543 | tafluprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87385 | Tafluprost | One source FDA |
| DrugBank | DB08819 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.